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Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised
patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal
trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for
evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses
Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for
assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are
discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans,
Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting
clinical, radiological, and/or mycological data and gaps in knowledge.
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Invasive fungal diseases (IFDs) are major causes of morbidity and mortality among
highly immunocompromised patients.
The European Organization for Research
and Treatment of Cancer (EORTC) and
the Mycoses Study Group (MSG) pub-
lished guidelines on definitions of IFDs for
clinical research [1, 2]. Bennett et al. [3–
5] previously discussed challenges in the
design of antifungal trials. Our objective
here is to establish consensus criteria for
evaluating therapeutic responses in phase
III trials of IFDs.
Although specific criteria for therapeu-
tic success vary for the major IFDs, global
response requires survival and a positive
effect on fungal disease (table 1). With cer-
tain IFDs (e.g., candidemia), cure is the
goal of therapy. The term, “documented
clearance” is more appropriate than “ster-
ilization,” because the yield of cultures can
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Table 1. General criteria for global responses to antifungal therapy.
Outcome, response Criteria
Success
Complete response Survival within the prespecified period of observation, resolution of all attributable symptoms and signs of disease
and radiological abnormalities, and mycological evidence of eradication of disease
Partial response Survival within the prespecified period of observation, improvement in attributable symptoms and signs of dis-
ease and radiological abnormalities, and evidence of clearance of cultures or reduction of fungal burden, as as-
sessed by a quantitative and validated laboratory marker
Failure
Stable responsea Survival within the prespecified period of observation and minor or no improvement in fungal disease, but no
evidence of progression, as determined on the basis of a composite of clinical, radiological, and mycological
criteria
Progression of fungal disease Evidence of progressive fungal disease based on a composite of clinical, radiological, and mycological criteria
Death Death during the prespecified period of evaluation, regardless of attribution
a In certain invasive fungal diseases (e.g., invasive mold diseases), stabilization of fungal disease during periods of severe immunocompromise provides
evidence of efficacy of treatment and may be a reasonable short-term therapeutic goal until immune recovery occurs.
vary, especially while patients are receiving
antifungals. In histoplasmosis and cryp-
tococcosis, a response soon after start of
therapy may be termed, “successful con-
trol of disease,” correctly implying that
cure may not have been achieved. Indeed,
the best proof of cure for these fungal dis-
eases is absence of relapse after cessation
of therapy. The observation period to meet
this high standard for certain IFDs may
involve years and would be impractical for
therapeutic trials. Therefore, we attempted
to strike a balance between these limita-
tions and practical end points that can be
incorporated into therapeutic trials.
The primary analysis should include all
patients in the intent-to-treat (ITT) or
modified intent-to-treat (MITT) groups.
Completion of the assigned treatment reg-
imen is generally a requirement for a suc-
cessful outcome. However, it is also rea-
sonable to make provision for “success
with modification,” as was done in a trial
that compared voriconazole with ampho-
tericin B therapy for invasive aspergillosis
in which the protocol, in effect, evaluated
2 different treatment regimens rather than
2 different drugs [6, 7].
CONFLICTING DATA
Recognizing when primary antifungal
therapy fails is often not straightforward,
particularly when data are inadequate or
conflicting [8–10]. Protocols should ide-
ally prespecify a rank order of the weight
given to specific categories of data, with
more weight generally given to objective
data (e.g., oxygen saturation) than to sub-
jective data (e.g., presence of dyspnea), as
well as to specific signs of fungal diseases
(e.g., facial swelling in invasive fungal si-
nusitis) than to less specific signs (e.g.,
fever).
Discordant clinical, radiological, and/or
mycological data may result from an in-
adequate period of evaluation. Selection
of time points for assessment of response
should account for the potential of early
conflicting data. A competing concern is
that longer periods of evaluation of re-
sponse may increase the likelihood of
seemingly unrelated events (e.g., relapsed
malignancy) that would confound the in-
terpretation of response to antifungal ther-
apy. Suggested minimum periods of ob-
servation for the major IFDs are included
in tables 2–5.
REQUIREMENT FOR SURVIVAL
The majority of panel members consid-
ered survival through at least the time of
assessment of the primary end point to be
necessary, although not sufficient, for a
successful outcome. Because mortality
may result from causes seemingly unre-
lated to the IFD, some panel members ar-
gued that more-direct markers of response
to antifungal treatment (e.g., clearance of
cultures or a reduction in the level of a
laboratory marker) should be used as pri-
mary end points instead of survival. Pres-
pecified criteria for attributable mortality
have been used in some studies of anti-
fungals [11–13]. Anaissie [14] argued that,
in patients with invasive aspergillosis (IA),
deaths for which there is no autopsy evi-
dence of persistent fungal disease should
be considered successful outcomes in trials
of antifungal agents.
Attribution of mortality is difficult in
patients with medically complex cases
[15], even for the minority for whom au-
topsies are performed. Drug toxicity may
influence survival in ways not obvious to
the investigator (e.g., drug-drug interac-
tions) [16] or at autopsy. In addition, the
interaction of antifungal drugs with host
immunity is an area of growing interest
[17–23]; such interactions cannot be en-
capsulated solely by fungal markers and
may influence survival in ways we do not
understand. Randomization is expected to
balance the effect of confounding variables
that affect survival in the ITT or MITT
analysis.
CANDIDEMIA AND OTHER
FORMS OF INVASIVE
CANDIDIASIS
In candidemia, documented clearance of
Candida species from the blood should be
a requirement for a successful outcome.
Symptoms and signs (e.g., fever) attrib-
utable to disease may persist, but such
signs are nonspecific and should not, by
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Table 2. Responses to antifungal therapy in patients with candidemia and other forms of invasive candidiasis.
Outcome, response Criteria
Success
Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Documented clearance of pathogen from the blood in cases of candidemia; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF)
If additional cultures are not feasible (e.g., in cases of candidiasis involving visceral organs), survival and resolution of all
attributable symptoms and signs of disease and radiological resolution can be equated with a complete response
Partial response Survival and improvement of attributable symptoms and signs of diseasea; plus
Documented clearance of blood in cases of candidemia; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF).
If additional cultures are not feasible, survival and resolution of attributable symptoms and signs of disease and radiologi-
cal improvement or stabilization can be equated with a partial responseb
Failure
Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Persistent isolation of Candida species from blood specimens or specimens from other sterile sites; or
If additional cultures are not feasible, radiological stabilization can be equated with a stable responseb
Progression of disease Persistent isolation of Candida species from blood specimens or specimens from other sterile sites in association with
worsening clinical symptoms or signs of disease (e.g., septic shock, progression of hematogenous cutaneous candidia-
sis); or
New sites of disease or worsening of preexisting lesions radiologically (e.g., those observed in chronic disseminated can-
didiasis) in association with clinical deterioration
Death Death during the prespecified period of evaluation regardless of attribution
NOTE. The minimum period of observation is 4 weeks after start of therapy. The rationale for this minimum period of evaluation is to detect relapses
of disease. Relapse generally requires a positive result of a culture of a specimen of blood or of another sterile site and not simply recurrence of symptoms
or signs (e.g., fever) that are generally nonspecific. In the specific cases of visceral organ involvement (e.g., endocarditis, meningitis, retinitis, or chronic
disseminated candidiasis), we suggest a period of observation of at least 12 weeks after start of therapy.
a Fever without localizing symptoms or other abnormal physical examination findings is the most common manifestation of candidemia. However,
because fever can result from multiple causes unrelated to candidemia, we suggest that more weight be given to documented clearance of pathogens
from the blood than to resolution of fever in the global assessment of response to therapy. Thus, the scenario of persistent or recurrent fever despite
clearance of blood should be assessed as at least a partial response and, therefore, equated with a successful response.
b In visceral candidiasis (e.g., hepatosplenic candidiasis) with negative blood culture results at baseline, persistent fever may be the only attributable
clinical sign of candidiasis, and radiological abnormalities can persist for prolonged periods. In such situations, resolution of fever and stable radiological
disease may be equated with a partial response. Laboratory markers, such as PCR and the (1r3)-b-d-glucan assay, have not been adequately validated
as markers of response to therapy for invasive candidiasis.
themselves, be equated with failure. Re-
moval of a central line may reduce the
time to clearance of blood cultures in cases
of candidemia [24]. However, unless the
protocol prespecifies removal of intrave-
nous catheters as a requirement for eli-
gibility, catheter removal should not be
considered in the outcome assessment.
Follow-up sampling of easily accessible
sites, such as CSF in patients with men-
ingitis and persistent joint fluid in those
with arthritis, should be required to eval-
uate therapeutic response. If follow-up
samples are not obtained, the response
should either be scored as indeterminate
or a failure if other signs of progressive or
poorly controlled disease (e.g., multiorgan
failure) occur.
The time to assess primary outcomes
in candidemia should not just encompass
clearance of blood but also be adequate to
detect early recrudescence of candidiasis
and mortality directly or indirectly related
to fungal disease. We suggest a period of
observation of at least 4 weeks from the
time of enrollment (table 2). In the view
of most of the panel members, end-of-
therapy response should be avoided as a
primary end point, because the time to
stop therapy can be variable, and end-of-
therapy successes will not capture early re-
lapses after discontinuation of therapy.
INVASIVE ASPERGILLOSIS
AND OTHER MOLD DISEASES
Evaluation of response to therapy in in-
vasive mold disease is difficult. In the
highly immunocompromised patient, fe-
ver and localizing physical examination
findings are often absent [25]. In addition,
some of the clinical manifestations of IA
may not necessarily indicate clinical de-
terioration. For example, hemoptysis is
more common after neutrophil recovery
[26] and may not signify refractory
disease.
Evaluation of radiological responses,
particularly at early time points, poses sev-
eral challenges. Caillot et al. [27] per-
formed sequential CTs on patients with
neutropenia and IA. Despite administra-
tion of effective antifungal treatment, lead-
ing to a positive clinical response in most
patients, the median volume of lesions in-
creased 4-fold during the first week of
therapy and remained stable during the
second week. This study has implications
with regard to the interpretation of results
of salvage therapy in which neutropenic
patients with IA could be enrolled after
only 7 days of standard antifungal therapy
on the basis of radiological worsening [8,
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Table 3. Responses to antifungal therapy in patients with invasive mold disease.
Outcome, response Criteria
Success
Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated
with a complete radiological response; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease in-
volving the palate, sinuses, or cutaneous lesions)
Partial response Survival and improvement of attributable symptoms and signs of diseasea; plus
At least 25% reduction in diameter of radiological lesion (s); plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease in-
volving the palate, sinuses, or cutaneous lesions)
In cases of radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion), resolu-
tion of all attributable symptoms and signs of fungal disease can be equated with a partial response
In cases of radiological stabilization, biopsy of an infected site (e.g., lung biopsy) showing no evidence of
hyphae and negative culture results can be equated with a partial response
Failure
Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion); or
Persistent isolation of mold or histological presence of invasive hyphae in infected sites
Progression of disease Worsening clinical symptoms or signs of disease; plus
New sites of disease or radiological worsening of preexisting lesions; or
Persistent isolation of mold species from infected sites
Death Death during the prespecified period of evaluation regardless of attribution
NOTE. The minimum period of observation is at least 6 weeks in trials of primary therapy, but assessment of outcome at week 12 or later should be
included as a secondary end point. For trials of salvage therapy, consider evaluation of the primary end point at least 12 weeks after enrollment.
a Clear evidence of a radiological response (reduction in diameter by at least 25% with no new sites of disease) should be given more weight than
subjective, nonspecific, or difficult-to-quantify symptoms or signs of disease. Thus, in the scenario of fungal pneumonia, we suggest that radiological
improvement with persistence of fever or cough should be scored as a partial response. Because radiological improvement often lags behind clinical
improvement, especially if a short-term period of evaluation is employed (see Invasive Aspergillosis and Other Mold Diseases), we suggest that radiological
stabilization and resolution of all attributable symptoms and signs of disease can also be equated with a partial response. See text for discussion of serum
galactomannan index as a promising correlate of therapeutic outcome.
28–32]. Cavitation coinciding with neu-
trophil recovery may also be incorrectly
equated with fungal disease progression
[27, 33–35]. There is inadequate knowl-
edge about the radiological evolution of
IA in nonneutropenic patients who re-
spond to antifungal therapy.
Repeated sampling of infected sites
(e.g., repeated lung biopsies) to evaluate
for response to therapy may not be feasible
or clinically warranted. In such cases, ra-
diological response can be equated with
control of disease. Other potential prob-
lems in assessing outcome are incorrect
diagnosis, mixed fungal diseases [25, 36],
and coexistent bacterial and fungal dis-
eases or noninfectious diseases.
Surgery as a therapeutic modality (e.g.,
for invasive craniofacial mold disease)
poses additional challenges for interpret-
ing therapeutic responses, because it is
generally not possible to judge the effect
of drug treatment alone. We suggest judg-
ing success or failure at the prespecified
time of analysis, without considering
whether surgery was performed. In a sec-
ondary analysis, patients treated with drug
alone versus with the drug plus surgery
may be analyzed separately.
In addition to facilitating the diagnosis
of IA, the galactomannan assay is also a
promising therapeutic marker [13, 37–
40]. Boutboul et al. [38] showed that se-
rum galactomannan index (GMI) values
significantly increased in patients with IA
who did not respond to antifungal ther-
apy, whereas no significant change oc-
curred in patients who responded to ther-
apy. Maertens et al. [37] reported that all
24 patients with IA with persistent or in-
creasing serum GMI values eventually died
of or with IA [37]. Woods et al. [41] dem-
onstrated the utility of serial GMI testing
as a predictor of outcome in patients with
multiple myeloma and IA. Miceli et al.
[42] defined immune reconstitution in-
flammatory syndrome (IRIS) as clinical
and radiological deterioration and reduc-
tion in serum GMI values coinciding with
neutrophil recovery in patients with IA
who subsequently cleared fungal disease
without a change in therapy. Serum GMI
has better performance as a diagnostic
marker in patients with hematological ma-
lignancies and allogeneic hematopoietic
stem cell transplant recipients than in
solid-organ transplant recipients [43],
suggesting that its utility as a therapeutic
marker may also be influenced by host
factors.
Anaissie [14] argued that serum GMI
values should be used both in practice and
in clinical trials as an early marker of ther-
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Table 4. Responses to antifungal therapy in cryptococcal meningitis.
Outcome, response Criteria
Success
Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Documented clearance of pathogen from CSF; plus
Documented clearance of pathogen from blood in cases of bloodstream disease; plus
Documented clearance of pathogen from other sites of disease (if additional cultures are performed); plus
Improvement or stabilization of radiological lesions if present (e.g., CNS cryptococcomaa)
Partial response Survival and improvement of attributable symptoms and signs of disease; plus
Documented clearance of pathogen from CSF; plus
Documented clearance of pathogen from blood in cases of bloodstream disease; plus
Documented clearance of pathogen from other sites of disease if additional cultures are performed; plus
Improvement or stabilization in radiological lesions if present at baseline
Failure
Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Persistently positive results of cultures of CSF specimens or specimens of other infected sites
Progression of disease Worsening clinical symptoms or signs of disease plus
Persistently positive results of cultures of CSF specimens or specimens of other infected sites; or
New sites of disease or worsening of preexisting lesions radiologically
Death Death during the prespecified period of evaluation, regardless of attribution
NOTE. The minimum period of observation is 10 weeks after the time of initiation of study drug. The rationale for this minimum period of evaluation is
that assessments of clinical and mycological responses may conflict at early time points.
a Disappearance of cryptococcoma can take years beyond cure of cryptococcal disease. Therefore, a complete or partial response can be assessed despite
persistence of these lesions.
apeutic response in IA. The majority of
panel members considered serial GMI
measurements to be a highly promising
therapeutic marker but believed that it was
currently premature to adopt serum GMI
value as a primary mycological end point
in clinical trials of IA; serum GMI mon-
itoring should be included as a secondary
end point. Serum (1r3)-b-d-glucan can
be a valuable diagnostic adjunct in a num-
ber of IFDs, including invasive candidiasis
and aspergillosis [2, 44, 45]. Data on the
utility of serum (1r3)-b-d-glucan mon-
itoring as a therapeutic marker are limited.
Clinical, radiological, and mycological
end points may conflict, particularly at
early time points [9, 10]. In the study com-
paring voriconazole with amphotericin B
as primary therapy for IA, the difference
in successful outcomes was apparent by 6
weeks [6]. Most deaths (50 [68%] of 73)
that occurred during the first 6 weeks were
attributable to IA; of the 25 deaths during
the second 6 weeks, only 6 (24%) were
attributed to IA [11]. However, in 2
pooled trials (P041 and P02387) that eval-
uated posaconazole as salvage therapy for
invasive mold diseases, the overall rate of
concordance between treatment responses
assessed at 1 and 3 months was only 42%
(C. Hardalo, Schering-Plough, personal
communication). The concordance be-
tween 3- and 6-month assessments
showed substantial improvement (76%).
For primary therapy trials of IA, most
of the panel members considered 6 weeks
after enrollment to be the minimum time
to assess the primary outcome end point.
An analysis at week 12 or later should be
included as a secondary end point. By ex-
trapolation, this period of observation is
reasonable for non-Aspergillus invasive
mold diseases. In salvage studies, a time
point of at least 12 weeks should be con-
sidered for the primary end point analysis.
CRYPTOCOCCAL MENINGITIS
C. neoformans disease most commonly
manifests as meningitis. Assessment of
treatment response in cryptococcal men-
ingitis relies on clinical and mycological
criteria [46–48]. Documented clearance of
CSF typically precedes the expected re-
duction in antigen titers in patients with
a response to antifungal therapy [46] and
is the “gold standard” to evaluate myco-
logical response. CSF specimens obtained
by lumbar puncture are likely to be more
sensitive for recovery of organisms than
are those obtained by intraventricular col-
lection; if the initial lumbar fluid specimen
yields positive results followed by a neg-
ative ventricular fluid specimen, no con-
clusion should be drawn. Clearance of
CSF is given more weight than clinical cri-
teria (e.g., fever and meningismus) in as-
sessing the global response. Thus, clear-
ance of CSF but persistence of fever or
headache should be equated with at least
a partial response.
IRIS results from an exuberant inflam-
matory response toward previously diag-
nosed infection or infection with incu-
bating pathogens (e.g., mycobacterial and
cytomegalovirus disease). IRIS is well de-
scribed in patients with AIDS-associated
cryptococcal meningitis after initiation of
antiretroviral therapy and manifests with
meningismus and elevated CSF opening
pressures, protein levels, and WBC counts
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Table 5. Responses to antifungal therapy in systemic histoplasmosis.
Outcome, response Criteria
Success
Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated
with a complete radiological response; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF)
If infected sites are not accessible to repeat sampling for cultures, clearance of Histoplasma antigen from
serum and urine (if detected at baseline) can be used as a mycological criterion for complete response.
Partial response Survival and improvement of attributable symptoms and signs of disease; plus
Improvement in radiological lesions; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF)
If infected sites are not accessible to repeated sampling for cultures, a decrease in the serum Histo-
plasma antigen level of at least 50% during the first 3 months of therapy, relative to the baseline level,
can be equated with a partial mycological response
Failure
Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Radiological stabilization; or
Persistently positive results of cultures of specimens from infected sites; or
If infected sites are not accessible to repeated sampling for culture, lack of a decrease in the serum Histo-
plasma antigen level of at least 50% after 3 months of therapy can be equated with a stable mycologi-
cal response
Progression of disease Worsening clinical symptoms or signs of disease; plus
New sites of disease or radiological worsening of preexisting lesions; or
Persistently positive results of cultures of specimens from infected sites; or
If infected sites are not accessible to repeated sampling for cultures, an increase in the serum Histo-
plasma antigen level of 120% can be a mycological criterion for worsening of disease
Death Death during the prespecified period of evaluation, regardless of attribution
NOTE. Three months from time of initiation of study drug is a suggested minimum period of observation for systemic histoplasmosis. Because some
patients develop relapsed disease while receiving antifungal therapy, assessment of outcome at 12 months after initiation of study drug is suggested as a
secondary end point.
[49–51]. Repeated CSF cultures are re-
quired to distinguish IRIS from persistent
or recrudescent cryptococcal disease. IRIS
does not represent treatment failure.
In CNS cryptococcal disease, neurolog-
ical sequelae, such as blindness and de-
mentia, can persist indefinitely and are not
due to persistent microbes. The absence
of fungal disease would meet the myco-
logical end point for a successful outcome
and, in fact, could be equated with cure
of disease. However, the majority of panel
members considered a measurable clinical
improvement to be a requisite for a suc-
cessful outcome in cases of cryptococcal
meningitis. This approach is consistent
with use of primary end points for ther-
apeutic trials of bacterial meningitis that
include neurological sequelae [52–57].
Repeated sampling of CSF is required
to assess the therapeutic response, because
clinical symptoms may not correlate with
control of disease. Use of systemic corti-
costeroids and other immunosuppressive
agents may blunt symptoms and signs of
meningitis. If an additional CSF sample is
not obtained, then the outcome should be
scored as “indeterminate” if a clinical re-
sponse occurs and as “failure” if clinical
findings are unchanged or worsen. In cases
of concurrent extraneural C. neoformans
disease, a mycological response involves
documented clearance of disease from in-
volved sites if repeated sampling is feasible
(e.g., blood cultures for fungemic
patients).
Brouwer et al. [58] evaluated antifungal
regimens in patients with AIDS-associated
cryptococcal meningitis, using the rate of
reduction in CSF colony-forming units
within the first 2 weeks as the primary end
point. Despite the low number of subjects,
this study identified amphotericin B plus
flucytosine as the most effective regimen.
In phase I/II studies in which patient ac-
crual is limited, such quantitative myco-
logical end points provide valuable data.
However, definitive phase III trials should
include longer-term end points and be ad-
equately powered to evaluate survival, per-
sistent morbidity, and drug toxicity.
ENDEMIC MYCOSES
Our guidelines focus on disseminated his-
toplasmosis and coccidioidomycosis.
Chronic fibrocavitary forms of pulmonary
histoplasmosis and coccidioidomycosis
may show little radiological improvement
with successful drug therapy. In menin-
gitis, clinical and mycological evidence of
control of disease are requisites of a suc-
cessful global response. Radiological res-
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olution of CNS fungal lesions is rarely
complete, even after years of observation.
Improvement of CT and MRI findings is
a more useful end point to judge success,
with the caveat that improvement in
edema can be associated with corticoste-
roid therapy. IRIS has been reported in
patients with AIDS-associated histoplas-
mosis receiving antiretroviral therapy [59]
and does not denote treatment failure.
Histoplasmosis. Clearance of blood
cultures is the gold standard for mycolog-
ical response in patients with histoplas-
mosis and positive blood culture results.
However, blood cultures, including those
that undergo lysis-centrifugation, are too
insensitive for results to be used as the sole
criterion to evaluate success. Culture re-
sults may be negative before commence-
ment of therapy and may yield only in-
termittently positive results during
unsuccessful therapy. Thus, clearance of
positive blood cultures is necessary, but
not sufficient, to determine whether an
outcome is successful.
Nonculture laboratory markers are use-
ful adjuncts in monitoring the response to
systemic histoplasmosis, with the provi-
sion that these tests should be conducted
using the same method and ideally in the
same reference laboratory. Although re-
sults of the Histoplasma antigen test has
not been used as a study end point in
clinical trials, changes in antigen findings
have paralleled those of culture in patients
with positive culture results [60–62]. In
patients with histoplasmosis and positive
blood culture results, clearance of funge-
mia is a better measure of antifungal effect
than is clearance of antigen [63]. However,
reduction in antigen levels could be used
as a mycological end point in patients with
negative blood culture results and as ad-
ditional evidence of response in patients
with positive culture results. Using a con-
servative measure, a decrease in the serum
antigen level by at least 50% during the
first 3 months of therapy relative to the
baseline level can be equated with a pos-
itive mycological response. In patients
whose antigen levels have decrease with
therapy, a subsequent increase of 20%
raises concern about relapse [64]. Antigen
levels were evaluated principally in AIDS-
associated disseminated histoplasmosis;
the predictive value of therapeutic re-
sponse in other patient populations has
not been established. Antigen levels in
urine may not decrease for several weeks,
even with effective therapy [65]; therefore,
persistent antigenuria should not be
equated with failure of therapy.
Coccidioidomycosis. Several trials of
coccidioidomycosis used a composite
scoring system to assess therapeutic re-
sponse [66–70]. Points were assigned on
the basis of (1) symptoms, (2) physical
examination findings, (3) quantitative
complement fixation titers (baseline and
follow-up titers measured in the same lab-
oratory concurrently), and (4) culture re-
sults. Numerical values were assigned on
the basis of prespecified rules, and the sum
of these values at reassessment was com-
pared with baseline values, with an in-
creasing score indicating deterioration. A
successful response required a 150% re-
duction in abnormal baseline findings8
months after commencement of therapy.
For patients with CNS coccidioido-
mycosis, life-long azole therapy is standard
because of the high frequency of recru-
descent disease if therapy is stopped [71,
72]. A composite numeric outcome score
using clinical and laboratory abnormali-
ties has been applied to coccidioidal men-
ingitis [73, 74]. In one study, a response
was defined as a40% reduction in base-
line abnormalities without subsequent re-
lapse during antifungal treatment [73]. A
patient who had not achieved this level of
improvement after 8 months was consid-
ered to be a nonresponder. For cocci-
dioidal meningitis, CSF specimens ob-
tained by lumbar puncture are likely to be
more sensitive for recovery of organisms
than are those obtained by intraventricular
collection; if the initial lumbar fluid spec-
imen yields a positive result followed by a
negative ventricular fluid result, no con-
clusion should be drawn. Moreover, ex-
cept in the rare patient with ventriculitis,
ventricular fluid findings may provide an
overly optimistic picture of the status of
the coccidioidal disease, with lower cell
counts, protein levels, and antibody titer
levels and higher glucose values, compared
with lumbar or cisternal fluid specimens;
this could be misleading if the scoring sys-
tem does not repeatedly evaluate the same
CSF compartment.
Chronic soft-tissue, bone, and pulmo-
nary disease are also characteristic of coc-
cidioidomycosis. Some of the original an-
tifungal salvage therapy trials involved
patients with persistent coccidioidomy-
cosis [75]. Therefore, in trials of these
forms of coccidioidomycosis, improve-
ment of clinical and laboratory end points
during therapy without eradication of dis-
ease may fulfill the criteria for a successful
outcome. A minority of patients with coc-
cidioidomycosis may require 9 months
to respond to antifungal therapy [76];
therefore, extension of the time to evaluate
the primary end point to, for example, 12
months is expected to change the outcome
for this subset of patients.
FUTURE PERSPECTIVES
To enhance trial efficiency, the US Food
and Drug Administration recommended
use of surrogate markers that can substi-
tute for clinical events as tools to increase
diagnostic specificity and to provide ob-
jective outcome measures [77]. Future tri-
als involving IFDs—particularly mold dis-
eases—should include validation of
laboratory assays as predictive correlates
of outcome. Such studies will ideally in-
clude prespecified serial monitoring of the
marker of interest measured at the same
reference laboratory. Future development
and validation of sensitive, non–culture-
based laboratory assays (e.g., PCR) and,
potentially, functional imaging modalities
(e.g., positron emission tomography [78])
may facilitate both the early diagnosis of
IFD and the assessment of therapeutic
response.
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